Broncus Holding Corporation
堃博医疗控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2216)

VOLUNTARY ANNOUNCEMENT

INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Broncus Holding Corporation (堃博医疗控股有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") wishes to announce that on December 12, 2024, it has resolved to exercise its powers under the general mandate (the "**Repurchase Mandate**") given to the Board pursuant to the resolution of the shareholders of the Company (the "**Shareholders**") passed in the annual general meeting of the Company held on May 20, 2024, to repurchase shares of the Company (the "**Shares**") in the open market from time to time (the "**Proposed Share Repurchase**"). The Proposed Share Repurchase will be funded by the Company's existing available cash. No repurchases would be made in circumstances that would have a material adverse impact on the working capital positions of the Company. The Company will subsequently cancel, hold in treasury, sell or transfer the repurchased Shares, if any, as deemed appropriate by the Board.

The financial position of the Company is currently solid and healthy. The Board considers that the current trading price of the Shares does not reflect their intrinsic value. The Board believes the Proposed Share Repurchase could enhance the value of the Shares thereby improving the return to Shareholders. In addition, the Board believes that the Proposed Share Repurchase reflects the Company's confidence in its long-term business prospects and growth potential of the Company, and would ultimately benefit the Company and is in the best interests of the Company and the Shareholders as a whole.

Pursuant to the Repurchase Mandate, the Board may repurchase Shares on The Stock Exchange of Hong Kong Limited a maximum of 52,719,807 Shares which represent 10% of the total number of the issued Shares (excluding treasury Shares) as at the date of passing the ordinary resolution approving the Repurchase Mandate (i.e. May 20, 2024), with such mandate to expire upon whichever is the earliest of: (i) the conclusion of the next annual general meeting of the Company; or (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held by the Companies Act, Cap. 22 (Act 3 of 1961, as consolidated and revised) of the Cayman Islands (the "**Cayman Companies Act**") or the articles of association of the Company (the "**Articles of Association**"); or (iii) the date upon which such authority is revoked or varied by a resolution of the Shareholders in general meeting prior to the next annual general meeting of the Company.

Under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the actual repurchase price of each Share shall be no more than 5% higher than the average closing market price for the Shares over the five (5) trading days immediately preceding each repurchase. The Proposed Share Repurchase shall not result in the number of the Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules. The Company will conduct the Proposed Share Repurchase in compliance with the Articles of Association, the Listing Rules, The Codes on Takeovers and Mergers and Share Buy-backs, the Cayman Companies Act and all applicable laws and regulations to which the Company is subject.

Shareholders and potential investors of the Company should note that the Proposed Share Repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of the Proposed Share Repurchase. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the Shares.

By order of the Board
Broncus Holding Corporation
XU Hong
Chairman

Hong Kong, December 12, 2024

As at the date of this announcement, the Board comprises Mr. Hong Xu as executive Director, Mr. Ao Zhang and Ms. Yanhong Kuang as non-executive Directors, and Dr. Pok Man Kam, Ms. Yee Sin Wong and Dr. David Scott Lim as independent non-executive Directors.